

# Shmuel Shoham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089664/publications.pdf>

Version: 2024-02-01

99  
papers

9,149  
citations

76322

40  
h-index

45310

90  
g-index

106  
all docs

106  
docs citations

106  
times ranked

13494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
2	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	5.8	708
3	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 760-769.	13.7	695
4	Deployment of convalescent plasma for the prevention and treatment of COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 2757-2765.	8.2	649
5	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. <i>Journal of Clinical Investigation</i> , 2020, 130, 6141-6150.	8.2	375
6	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 521-526.	9.1	329
7	The immune response to fungal infections. <i>British Journal of Haematology</i> , 2005, 129, 569-582.	2.5	327
8	Toll-Like Receptor 4 Mediates Intracellular Signaling Without TNF- $\alpha$ Release in Response to <i>Cryptococcus neoformans</i> Polysaccharide Capsule. <i>Journal of Immunology</i> , 2001, 166, 4620-4626.	0.8	301
9	Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 882-913.	4.9	293
10	The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts. <i>Clinical Infectious Diseases</i> , 2014, 58, 214-224.	5.8	197
11	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. <i>New England Journal of Medicine</i> , 2022, 386, 1700-1711.	27.0	194
12	Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen <i>Cryptococcus neoformans</i> In Vivo. <i>Infection and Immunity</i> , 2004, 72, 5373-5382.	2.2	173
13	Acute Bacterial Suppurative Thyroiditis: A Clinical Review and Expert Opinion. <i>Thyroid</i> , 2010, 20, 247-255.	4.5	173
14	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	170
15	Invasive fungal infections in solid organ transplant recipients. <i>Future Microbiology</i> , 2012, 7, 639-655.	2.0	142
16	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	5.8	142
17	Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen Interaction. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4744-4748.	3.9	138
18	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1262-1275.	3.0	129

#	ARTICLE	IF	CITATIONS
19	Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. <i>Transplantation</i> , 2016, 100, e74-e80.	1.0	120
20	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	5.8	109
21	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. <i>Lancet, The</i> , 2021, 397, 562-564.	13.7	105
22	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	4.0	98
23	Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 637-640.	2.0	97
24	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. <i>Journal of Infectious Diseases</i> , 2020, 222, 1974-1984.	4.0	96
25	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 500-511.	10.7	85
26	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	10.7	83
27	Operation Warp Speed: implications for global vaccine security. <i>The Lancet Global Health</i> , 2021, 9, e1017-e1021.	6.3	72
28	Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. <i>Medical Mycology</i> , 2010, 48, 511-517.	0.7	68
29	<i>Cryptococcus neoformans</i> Meningitis at 2 Hospitals in Washington, D.C.: Adherence of Health Care Providers to Published Practice Guidelines for the Management of Cryptococcal Disease. <i>Clinical Infectious Diseases</i> , 2005, 40, 477-479.	5.8	66
30	Correcting COVID-19 vaccine misinformation. <i>EClinicalMedicine</i> , 2021, 33, 100780.	7.1	63
31	Real-World Experience with Echinocandin MICs against <i>Candida</i> Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1897-1906.	3.2	59
32	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	58
33	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. <i>MBio</i> , 2021, 12, .	4.1	57
34	Pneumocystis pneumonia in children. <i>Paediatric Respiratory Reviews</i> , 2009, 10, 192-198.	1.8	54
35	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	3.0	54
36	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , 2021, 8, 684151.	2.6	50

#	ARTICLE	IF	CITATIONS
37	Emerging fungal infections in solid organ transplant recipients: Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13525.	1.6	49
38	Invasive Fungal Infections in the ICU. <i>Journal of Intensive Care Medicine</i> , 2010, 25, 78-92.	2.8	46
39	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2021, 39, 101053.	7.1	45
40	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	5.8	44
41	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.9	43
42	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. <i>Blood Advances</i> , 2022, 6, 3678-3683.	5.2	42
43	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope registry. <i>Mycoses</i> , 2020, 63, 437-442.	4.0	41
44	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa574.	0.9	41
45	Emerging Fungal Infections in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 305-316.	5.1	38
46	The silent and dangerous inequity around access to COVID-19 testing: A call to action. <i>EClinicalMedicine</i> , 2022, 43, 101230.	7.1	33
47	Amikacin and colistin for treatment of <i>Acinetobacter baumannii</i> meningitis. <i>Journal of Infection</i> , 2005, 51, e249-e251.	3.3	32
48	Total Penis, Scrotum, and Lower Abdominal Wall Transplantation. <i>New England Journal of Medicine</i> , 2019, 381, 1876-1878.	27.0	31
49	Impact of Multidrug-Resistant Organisms on Patients Considered for Lung Transplantation. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 343-358.	5.1	30
50	Candidemia in Patients with Ventricular Assist Devices. <i>Clinical Infectious Diseases</i> , 2007, 44, e9-e12.	5.8	29
51	Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. <i>Journal of Clinical Virology</i> , 2021, 145, 104997.	3.1	28
52	The pharmacology and clinical use of caspofungin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 263-274.	3.3	26
53	Pulmonary Zygomycosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 111-120.	2.1	26
54	Management of Indwelling Tunneled Pleural Catheters. <i>Chest</i> , 2020, 158, 2221-2228.	0.8	25

#	ARTICLE	IF	CITATIONS
55	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. <i>Vox Sanguinis</i> , 2021, 116, 766-773.	1.5	22
56	High Proportion of Indeterminate Qu. jpegERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu088.	0.9	18
57	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. <i>Mycoses</i> , 2019, 62, 413-417.	4.0	18
58	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13521.	1.7	18
59	The Assessment of Convalescent Plasma Efficacy against COVID-19. <i>Med</i> , 2020, 1, 66-77.	4.4	17
60	Cardiac assist device infections. <i>Current Infectious Disease Reports</i> , 2009, 11, 268-273.	3.0	16
61	Transplant of SARS-CoV-2â€infectd Living Donor Liver: Case Report. <i>Transplantation Direct</i> , 2021, 7, e721.	1.6	16
62	Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. <i>Clinical Infectious Diseases</i> , 2022, 74, 1691-1695.	5.8	16
63	Effects of Immunomodulatory and Organism-Associated Molecules on the Permeability of an <i>In Vitro</i> Blood-Brain Barrier Model to Amphotericin B and Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1305-1310.	3.2	15
64	<i>Cryptococcus neoformans</i> Prosthetic Joint Infection: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2015, 179, 275-278.	3.1	15
65	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	3.0	15
66	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	1.6	14
67	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	1.6	13
68	Pharmacokinetics of high-titer antiâ€SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	5.0	12
69	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, .	5.0	12
70	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV</i> , 2020, 7, e602-e610.	4.7	11
71	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. <i>EclinicalMedicine</i> , 2021, 36, 100925.	7.1	11
72	Early serum (1â†³)â€D-glucan levels in patients with burn injury. <i>Mycoses</i> , 2012, 55, 224-227.	4.0	10

#	ARTICLE	IF	CITATIONS
73	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
74	Quantifying infection risks in incompatible living donor kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 1564-1575.	4.7	9
75	Association Between Blood Glucose Levels and Development of Candidemia in Hospitalized Patients. <i>Endocrine Practice</i> , 2009, 15, 111-115.	2.1	8
76	Graded isavuconazole introduction in a patient with voriconazole allergy. <i>Transplant Infectious Disease</i> , 2017, 19, e12772.	1.7	8
77	Single Academic Center Experience of Unrestricted $\beta$ -D-Glucan Implementation. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy195.	0.9	8
78	Urgent needs to accelerate the race for COVID-19 therapeutics. <i>EClinicalMedicine</i> , 2021, 36, 100911.	7.1	7
79	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. <i>PLoS Medicine</i> , 2021, 18, e1003772.	8.4	7
80	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 221-228.	3.0	6
81	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	2.2	6
82	Angioinvasive, cutaneous infection due to <i>Colletotrichum siamense</i> in a stem cell transplant recipient: Report and review of prior cases. <i>Transplant Infectious Disease</i> , 2019, 21, e13153.	1.7	5
83	Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 374-375.	1.8	4
84	Host/Pathogen Interactions in Fungal Keratitis. <i>Current Fungal Infection Reports</i> , 2015, 9, 52-56.	2.6	4
85	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	5.8	3
86	Treatment of Iatrogenic Fungal Infections: A Black Mold Defines a New Gray Zone in Medicine. <i>Annals of Internal Medicine</i> , 2013, 158, 208.	3.9	3
87	Antimicrobial Access in the 21st Century: Delays and Critical Shortages. <i>Annals of Internal Medicine</i> , 2016, 165, 53.	3.9	3
88	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. <i>Clinical Infectious Diseases</i> , 2022, 74, 1686-1690.	5.8	3
89	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. <i>Critical Care Medicine</i> , 2021, 49, e1265-e1266.	0.9	3
90	The Role of Genetics in Host Responses to Mucosal and Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2011, 5, 262-268.	2.6	2

#	ARTICLE	IF	CITATIONS
91	Neurosyphilis Masquerading as Herpes Encephalitis. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, 30-31.	0.3	1
92	Augmentation of innate host defenses against opportunistic fungal pathogens. <i>Current Fungal Infection Reports</i> , 2009, 3, 186-191.	2.6	1
93	Evaluation of <i>mupA</i> Evigene in Comparison to Disk Diffusion for Detection of High-Level Mupirocin Resistance in Clinical Isolates of <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 2953-2954.	3.9	1
94	Invasive Candidiasis in Patients with Implants. <i>Current Fungal Infection Reports</i> , 2011, 5, 12-17.	2.6	1
95	Updates on the Treatment of Non-Aspergillus Hyaline Mold Infections. <i>Current Fungal Infection Reports</i> , 2019, 13, 308-319.	2.6	1
96	Serial Spinal Taps Prevent Complications from Elevated CSF Pressure in Cryptococcal Meningitis. <i>Current Fungal Infection Reports</i> , 2010, 4, 200-202.	2.6	0
97	Epidemiological and Microbiological Features of Ventricular Assist Device Associated Infections. <i>Journal of Cardiac Failure</i> , 2010, 16, S115.	1.7	0
98	The Growing Role of Clinical and Genomic Databases in the Development of Antifungal Strategies. <i>Current Fungal Infection Reports</i> , 2011, 5, 190-192.	2.6	0
99	2686. <i>strong&gt;</i> Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Viridans Group <i>Streptococcus</i> Emerges as an Important Pathogen. <i>Open Forum Infectious Diseases</i> , 2019, 6, S943-S944.	0.9	0